Evidence map›Paper›PMID 37834660›Full record

ArticleMaterials (Basel, Switzerland)2023

Blood Compatibility of Drug-Inorganic Hybrid in Human Blood: Red Blood Cell Hitchhiking and Soft Protein Corona.

Jing Xie, Hyoung-Mi Kim, Kai Kamada, Jae-Min Oh

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jing XieDepartment of Energy and Materials Engineering, Dongguk University-Seoul, Seoul 04620, Republic of Korea.ORCID 0000-0002-5301-7450
Hyoung-Mi KimBiomedical Manufacturing Technology Center, Daegyeong Division, Korea Institute of Industrial Technology (KITECH), Yeongcheon-si 38822, Republic of Korea.ORCID 0000-0002-4858-1022
Kai KamadaDepartment of Materials Science and Engineering, Faculty of Engineering, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
Jae-Min OhDepartment of Energy and Materials Engineering, Dongguk University-Seoul, Seoul 04620, Republic of Korea.ORCID 0000-0003-1638-9957
Dongguk University · KRKorea Institute of Industrial Technology · KRNagasaki University · JP

Funding

Korea Water Cluster (KWC) Korea Water Cluster ProjectLabMinistry of Science and ICT (MSIT, Korea) & Korean National Police Agency RS-2023-00236429
6 · The paper itself

Abstract

A drug-delivery system consisting of an inorganic host-layered double hydroxide (LDH)-and an anticancer drug-methotrexate (MTX)-was prepared via the intercalation route (MTX-LDH), and its hematocompatibility was investigated. Hemolysis, a red blood cell counting assay, and optical microscopy revealed that the MTX-LDH had no harmful toxic effect on blood cells. Both scanning electron microscopy and atomic force microscopy exhibited that the MTX-LDH particles softly landed on the concave part inred blood cells without serious morphological changes of the cells. The time-dependent change in the surface charge and hydrodynamic radius of MTX-LDH in the plasma condition demonstrated that the proteins can be gently adsorbed on the MTX-LDH particles, possibly through protein corona, giving rise to good colloidal stability. The fluorescence quenching assay was carried out to monitor the interaction between MTX-LDH and plasma protein, and the result showed that the MTX-LDH had less dynamic interaction with protein compared with MTX alone, due to the capsule moiety of the LDH host. It was verified by a quartz crystal microbalance assay that the surface interaction between MTX-LDH and protein was reversible and reproducible, and the type of protein corona was a soft one, having flexibility toward the biological environment.

Indexed as

biocompatibilityblood compatibilitydrug-delivery systemhitchhikinghuman plasmalayered double hydroxidemethotrexateprotein coronared blood cell

Identifiers

PMID37834660
PMCPMC10573551
OpenAlexW4387258942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.